

# WOAH Reference Laboratory Reports Activities 2023

## Activities in 2023

This report has been submitted : 7 juin 2024 05:23

### Laboratory Information

<b>Name of disease (or topic) for which you are a designated WOAHO Reference Laboratory:</b>	Infection with yellow head virus genotype 1
<b>Address of laboratory:</b>	CSIRO Australian Centre for Disease Preparedness, 5 Portarlington Road, East Geelong VIC 3220 Australia
<b>Tel.:</b>	+61-3 52 27 5749
<b>E-mail address:</b>	moo310@csiro.au
<b>Website:</b>	<a href="https://www.csiro.au/en/about/facilities-collections/ACDP/Aquatic-Animal-Health">https://www.csiro.au/en/about/facilities-collections/ACDP/Aquatic-Animal-Health</a>
<b>Name (including Title) of Head of Laboratory (Responsible Official):</b>	Dr Debbie Eagles, Director, Australian Centre for Disease Preparedness
<b>Name (including Title and Position) of WOAHO Reference Expert:</b>	Dr Nick Moody, Research Group Leader, ACDP Fish Diseases Laboratory
<b>Which of the following defines your laboratory? Check all that apply:</b>	Governmental

### TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.?

(Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAHO Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests		Nationally	Internationally
Direct diagnostic tests		Nationally	Internationally
AFDL YHV1 RT-qPCR		31	58
AFDL YHV1 RT-nPCR		2	0

### TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAHO?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAHO Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOAHO MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
Gamma-irradiated YHV1-infected haemolymph	Molecular tests	Provided	0	3 x 500uL	2	KOREA (REP. OF), SRI LANKA,

4. Did your laboratory produce vaccines?

Not applicable

5. Did your laboratory supply vaccines to WOAHA Members?

Not applicable

### **TOR3: NEW PROCEDURES**

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAHA Standards for the designated pathogen or disease?

Yes

NAME OF THE NEW TEST OR DIAGNOSTIC METHOD DEVELOPED	DESCRIPTION AND REFERENCES (PUBLICATION, WEBSITE, ETC.)
AFDL YHV1 RT-qPCR	WOAHA Validation Report Template for YHV1 [ <a href="https://www.woaha.org/app/uploads/2024/03/validation-report-template-yhv1.pdf">https://www.woaha.org/app/uploads/2024/03/validation-report-template-yhv1.pdf</a> ]

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOAHA Standards for the designated pathogen or disease?

No

### **TOR4: DIAGNOSTIC TESTING FACILITIES**

10. Did your laboratory carry out diagnostic testing for other WOAHA Members?

Yes

NAME OF WOAHA MEMBER COUNTRY SEEKING ASSISTANCE	DATE	WHICH DIAGNOSTIC TEST USED	NO. SAMPLES RECEIVED FOR PROVISION OF DIAGNOSTIC SUPPORT	NO. SAMPLES RECEIVED FOR PROVISION OF CONFIRMATORY DIAGNOSES
PAPUA NEW GUINEA	2023-02-01	AFDL YHV1 RT-qPCR	36	0

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHA Member?

Yes

NAME OF THE WOAHA MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
PAPUA NEW GUINEA	Implementation of molecular test capability for YHV1	Email, face-to-face

### **TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES**

12. Did your laboratory participate in international scientific studies in collaboration with WOAHA Members other than the own?

No

13. In exercising your activities, have you identified any regulatory research needs\* relevant for WOAHA?

No

### **TOR6: EPIZOOLOGICAL DATA**

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

0

b) International conferences:

0

c) National conferences:

0

d) Other (Provide website address or link to appropriate information):

0

## TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA Members?

Yes

a) Technical visit : 4

b) Seminars : 0

c) Hands-on training courses: 3

d) Internships (&gt;1 month) 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
A	PAPUA NEW GUINEA	10
C	PAPUA NEW GUINEA	3

## TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO17025	PDF	NATA ISO 17025 SEP 2022.pdf
ISO17043	PDF	NATA ISO 17043 NOV 2022.pdf
ISO9001	PDF	BSI ISO 9001 NOV 2022.pdf
ISO14001	PDF	BSI ISO 14001 NOV 2022.pdf

19. Is your quality management system accredited?

No

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

The laboratory has a dedicated Biorisk Management Team (14 Members) who provide specialist advice, monitor and improve Biosafety, Biosecurity and Biocontainment activities and perform maintenance on Biocontainment systems. The team uses a risk analysis approach to management of biological risks for biosafety and biosecurity to inform and determine the policy and procedures that in turn give confidence that the laboratory procedures for each of the biological materials handled by the laboratory pose negligible danger to Australia's animal and human populations. 261 Policies and procedures are contained in the annually reviewed ACDP Biorisk Manual consisting of various sections as follows. Section 1 Administration Section 2 PC2 Procedures and Policies Section 3 PC3 Procedures and Policies Section 4 PC4 Procedures and Policies Section 5 Large Animal Facility (LAF) Procedures and Policies Section 6 Personnel and Procedural Controls Section 7 Transport and Storage of Biological Material Section 8 Movement of Material, Equipment and Waste Section 9 Engineering Procedures and Policies Section 10 Microbiological Incident Response Procedures and Policies Section 11 Laboratory Services Group Section 12 Containment Services Group The successful ACDP biological risk management system has clear and unequivocal commitment by laboratory management, who ensure that roles, responsibilities, resources and authorities related to biological risk management are defined, documented, and

communicated to those who manage, perform, and verify work associated with biological agents and toxins in the laboratory. The Biorisk Management Team are audited over 3 days every 6 months by an external security assessment team to provide an independent review of elements affecting ACDP's microbiological and physical security operations and to advise CSIRO senior executive management of any areas of concern or risk. The laboratory is aspiring to become accredited to ISO 35001:2019 Biorisk management for laboratories and other related organisations.

## TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?H?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?H?

No

## TOR10: NETWORK WITH WOA?H REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA?H Reference Laboratories designated for the same pathogen or disease?

Not applicable (only WOA?H Reference Laboratory designated for the disease)

24. Do you network (collaborate or share information) with other WOA?H Reference Laboratories designated for the same pathogen?

Not applicable (Only WOA?H Reference Laboratory designated for the disease)

25. Did you organise or participate in inter-laboratory proficiency tests with WOA?H Reference Laboratories designated for the same pathogen?

Not applicable (Only WOA?H Reference Laboratory designated for the disease)

26. Did your laboratory collaborate with other WOA?H Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Not applicable (Only WOA?H Reference Laboratory designated for the disease)

## TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA?H Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons <sup>1</sup>	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the Test	WOA?H Member Countries
Determining a laboratory's capability to conduct specific diagnostic tests	Participant	25	EURL Inter-laboratory Proficiency Test 2023	DENMARK,
Determining a laboratory's capability to conduct specific diagnostic tests	Organiser and participant	10	Australian National Aquatic Proficiency Testing Program	AUSTRALIA,
Asia-Pacific Aquatic PT Program	Organiser	32	Asia-Pacific Aquatic PT Program	

## TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?H?

Yes

KIND OF CONSULTANCY	Location	SUBJECT (FACULTATIVE)
Invited participant	Busan, Republic of Korea, June 26 to 28, 2023	Regional Workshop for WOA?H Focal Points for Aquatic Animals
Invited participant	Busan, Republic of Korea, 29 June 2023	4th meeting of ad hoc Steering Committee of Regional Collaboration Framework on Aquatic Animal Health in Asia and the Pacific
Facilitator	Pretoria, South Africa, 5 - 7 December 2023	Establishment of a Regional Aquatic Animal Health Laboratory Network (RAAHLN) for Africa
Technical papers on diagnostic test procedures	Electronic	Complete and submitted the YHV1 RT-qPCR WOA?H Validation Dossier

29. Additional comments regarding your report:

Yes

*Regarding Point 3. "Did your laboratory supply standard reference reagents (non-WOAH-approved) and/or other diagnostic reagents to WOAH Members?" – I only include YHV1 reagents here but we have also supplied positive control material for IMNV, CMNV, TSV and DVI1. Would you like these to also be included in future Annual Reports?*